Current Edition

CAP-1002

Capricor Announces Initiation Of HOPE-2 Clinical Trial Of CAP-1002 For Duchenne Muscular Dystrophy

Capricor Therapeutics, Inc. (NASDAQ:CAPR) today announced it has initiated the HOPE-2 clinical trial at UC Davis Medical Center. The trial will test the safety and efficacy …

Continue Reading →